Francesco Sbrana

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9386997/publications.pdf

Version: 2024-02-01

471061 476904 1,041 104 17 29 citations h-index g-index papers 104 104 104 1494 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Carbapenem-Sparing Antibiotic Regimens for Infections Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Intensive Care Unit. Clinical Infectious Diseases, 2013, 56, 697-700.	2.9	92
2	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet, The, 2022, 399, 719-728.	6.3	69
3	Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study. Atherosclerosis Supplements, 2017, 29, 17-24.	1.2	65
4	Tangier Disease. American Journal of Cardiovascular Drugs, 2012, 12, 303-311.	1.0	62
5	Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy. Advances in Therapy, 2017, 34, 1200-1210.	1.3	56
6	Oral Gentamicin Gut Decontamination for Prevention of KPC-Producing Klebsiella pneumoniae Infections: Relevance of Concomitant Systemic Antibiotic Therapy. Antimicrobial Agents and Chemotherapy, 2014, 58, 1972-1976.	1.4	55
7	Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN). Atherosclerosis Supplements, 2017, 29, 11-16.	1.2	53
8	Tangier Disease. American Journal of Cardiovascular Drugs, 2012, 12, 303-311.	1.0	38
9	The role of biofilm forming on mortality in patients with candidemia: a study derived from real world data. Infectious Diseases, 2018, 50, 214-219.	1.4	29
10	Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features. Atherosclerosis, 2020, 312, 72-78.	0.4	25
11	Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study. European Journal of Preventive Cardiology, 2022, 29, 832-841.	0.8	23
12	Procalcitonin, white blood cell count and C-reactive protein as predictors of S. aureus infection and mortality in infective endocarditis. International Journal of Cardiology, 2020, 301, 190-194.	0.8	22
13	Independent risk factors for mortality in critically ill patients with candidemia on Italian Internal Medicine Wards. Internal and Emergency Medicine, 2018, 13, 199-204.	1.0	21
14	Impact of infectious diseases consultation as a part of an antifungal stewardship programme on candidemia outcome in an Italian tertiary-care, University hospital. Journal of Chemotherapy, 2018, 30, 304-309.	0.7	21
15	PCSK9 Inhibitors' New Users: Analysis of Prescription Patterns and Patients' Characteristics from an Italian Real-world Study. Clinical Drug Investigation, 2020, 40, 173-181.	1.1	21
16	Blood ozonization in patients with mild to moderate COVID-19 pneumonia: a single centre experience. Internal and Emergency Medicine, 2021, 16, 669-675.	1.0	19
17	Tangier Disease in Severely Progressive Coronary and Peripheral Artery Disease. Circulation, 2009, 119, 2741-2742.	1.6	17
18	Peripherally inserted central catheter as a predominant risk factor for candidemia in critically ill patients in Internal Medicine wards in Italy. Intensive Care Medicine, 2015, 41, 1498-1499.	3.9	17

#	Article	IF	CITATIONS
19	Reduced incidence of cardiovascular events in hyper-Lp(a) patients on lipoprotein apheresis. The G.I.L.A. (Gruppo Interdisciplinare Aferesi Lipoproteica) pilot study. Transfusion and Apheresis Science, 2018, 57, 661-664.	0.5	17
20	Personalized machine learning approach to predict candidemia in medical wards. Infection, 2020, 48, 749-759.	2.3	17
21	Myeloperoxidase modulation by LDL apheresis in Familial Hypercholesterolemia. Lipids in Health and Disease, 2011, 10, 185.	1.2	16
22	Candidemia in Patients with Body Temperature Below 37°C and Admitted to Internal Medicine Wards: Assessment of Risk Factors. American Journal of Medicine, 2016, 129, 1330.e1-1330.e6.	0.6	16
23	Personalized regimen for PCSK9 inhibitors: A therapeutic option that maintains efficacy and reduces costs. Journal of Clinical Lipidology, 2018, 12, 1324-1325.	0.6	16
24	Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey. Orphanet Journal of Rare Diseases, 2021, 16, 381.	1.2	12
25	Routine laboratory tests to risk-stratify patients with chronic coronary artery disease. Journal of Cardiology, 2013, 61, 132-137.	0.8	11
26	Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?. European Journal of Preventive Cardiology, 2017, 24, 1528-1531.	0.8	10
27	Clinical outcomes of elderly patients with bloodstream infections due to extended-spectrum β-lactamase–producing Enterobacteriaceae in an Italian Internal Medicine ward. European Journal of Internal Medicine, 2018, 48, 50-56.	1.0	10
28	A prediction rule for early recognition of patients with candidemia in Internal Medicine: results from an Italian, multicentric, case–control study. Infection, 2018, 46, 625-633.	2.3	10
29	Elusive Therapeutic Effect of PCSK9 Inhibitors on Lipoprotein(a) Levels. Therapeutic Apheresis and Dialysis, 2019, 23, 385-386.	0.4	10
30	Risk factors for ventilator associated pneumonia due to carbapenemase-producing Klebsiella pneumoniae in mechanically ventilated patients with tracheal and rectal colonization. Minerva Anestesiologica, 2016, 82, 635-40.	0.6	10
31	LDL apheresis improves coronary flow reserve on the left anterior descending artery in patients with familial hypercholesterolemia and chronic ischemic heart disease. Atherosclerosis Supplements, 2017, 30, 135-140.	1.2	9
32	A large Italian cohort on proprotein convertase subtilisin/kexin type 9 inhibitors. European Journal of Preventive Cardiology, 2020, 27, 2284-2287.	0.8	9
33	Phenotypic variability in 4 homozygous familial hypercholesterolemia siblings compound heterozygous for LDLR mutations. Journal of Clinical Lipidology, 2016, 10, 944-952.e1.	0.6	8
34	Ceftazidine-avibactam salvage therapy in newborn with KPC-producing Klebsiella pneumoniae invasive infections. Minerva Anestesiologica, 2019, 85, 804-805.	0.6	7
35	CORonavirus-19 mild to moderate pneumonia Management with blood Ozonization in patients with Respiratory failure (CORMOR) multicentric prospective randomized clinical trial. International Immunopharmacology, 2021, 98, 107874.	1.7	7
36	A massive retroperitoneal hematoma during low-molecular-weight-heparin therapy. Internal and Emergency Medicine, 2016, 11, 153-154.	1.0	6

#	Article	IF	Citations
37	Cardiac tamponade due to apixaban therapy in patient with unknown pericardial hemangioma. Internal and Emergency Medicine, 2018, 13, 297-299.	1.0	6
38	Adverse events and humoral response after two doses of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) mRNA vaccine in the hospital personnel of a cardiopulmonary tertiary-care center. Infection Control and Hospital Epidemiology, 2022, 43, 1532-1534.	1.0	6
39	High Density Lipoprotein Cholesterol in Coronary Artery Disease: When Higher Means Later. Journal of Atherosclerosis and Thrombosis, 2013, 20, 23-31.	0.9	5
40	Ventilator-associated pneumonia caused by colistin-resistant KPC-producing Klebsiella pneumoniae: A case report and literature review. Respiratory Investigation, 2015, 53, 124-128.	0.9	5
41	Dabigatran malabsorption in amiodarone-induced thyrotoxicosis: a clinical report. Internal and Emergency Medicine, 2016, 11, 889-890.	1.0	5
42	Null receptor homozygous familial hypercholesterolaemia: <i>Quoad valetudinem</i> long life treatment. European Journal of Preventive Cardiology, 2020, 27, 2105-2108.	0.8	5
43	Statins during daptomycin therapy: to give or not to give?. Minerva Anestesiologica, 2019, 85, 689-690.	0.6	5
44	Arterial blood culture to hasten the diagnosis of candidemia in critically ill patients. Intensive Care Medicine, 2014, 40, 1059-1060.	3.9	4
45	Safety and Utility of Noninvasive Ventilation During Deep Sedation for Catheter Ablation of Atrial Fibrillation. Journal of Cardiothoracic and Vascular Anesthesia, 2014, 28, e6-e8.	0.6	4
46	Anesthetic management in atrial fibrillation ablation procedure: Adding non-invasive ventilation to deep sedation. Indian Pacing and Electrophysiology Journal, 2015, 15, 96-102.	0.3	4
47	Mediastinal dedifferentiated liposarcoma. Acta Cardiologica, 2017, 72, 499-500.	0.3	4
48	Potential role of IgM-enriched immunoglobulin as adjuvant treatment for invasive meningococcal disease. Intensive Care Medicine, 2018, 44, 261-262.	3.9	4
49	Antifungal Stewardship Programs and Candidemia. Clinical Infectious Diseases, 2020, 70, 1522-1523.	2.9	4
50	Effect of proprotein convertase subtilisin/kexin type 9 inhibitors on lipoprotein(a) still to be unravelled. European Journal of Preventive Cardiology, 2019, 26, 782-782.	0.8	4
51	Changes in Plasma Bioactive Lipids and Inflammatory Markers during a Half-Marathon in Trained Athletes. Applied Sciences (Switzerland), 2021, 11, 4622.	1.3	4
52	New inflammatory and oxidative stress-based biomarker changes in response to a half-marathon in recreational athletes. Journal of Sports Medicine and Physical Fitness, 2020, 60, 1390-1395.	0.4	4
53	Aseptic meningitis as onset of Kawasaki disease. Minerva Pediatrica, 2020, 72, 135-137.	2.6	4
54	Rhabdomyolysis in an HIV-infected patient following coronary angiography: case report and literature review. International Journal of STD and AIDS, 2014, 25, 452-454.	0.5	3

#	Article	IF	CITATIONS
55	Early senescence in heterozygous ABCA1 mutation skin fibroblasts: A gene dosage effect beyond HDL deficiency?. Biochemical and Biophysical Research Communications, 2014, 447, 231-236.	1.0	3
56	Calcified apical cardiomyopathy. Journal of Cardiovascular Medicine, 2015, 16, S79-S80.	0.6	3
57	T wave abnormalities identify patients with previous lateral wall myocardial infarction and circumflex artery disease. Journal of Electrocardiology, 2016, 49, 216-222.	0.4	3
58	Risk factors for candidaemia in critically ill patients in intensive care units as compared to internal medicine wards. Infectious Diseases, 2017, 49, 153-154.	1.4	3
59	Evolocumab improves intima media thickness regression in HeFH subjects on lipoprotein apheresis. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 2417-2419.	1.1	3
60	Recognition in Emergency Department of Septic Patients at Higher Risk of Death: Beware of Patients without Fever. Medicina (Lithuania), 2021, 57, 612.	0.8	3
61	A case of pulseless electrical activity secondary to pulmonary embolism: A medical emergency occurring in an LDL apheresis center. Transfusion and Apheresis Science, 2015, 53, 74-75.	0.5	2
62	Oral administration of gentamicin for prophylaxis of KPC-producing Klebsiella pneumoniae gut colonization in patients treated with a novel parenchymal-sparing liver surgery: the GEN Gut study. Intensive Care Medicine, 2016, 42, 124-125.	3.9	2
63	Analysis of Serum Cholesterol Efflux Capacity in a Minipig Model of Nonischemic Heart Failure. Journal of Atherosclerosis and Thrombosis, 2017, 24, 853-862.	0.9	2
64	Heterozygous familial hypercholesterolemia and HIV infection: The appropriate therapeutic flow chart is still to be written?. European Journal of Preventive Cardiology, 2018, 25, 503-504.	0.8	2
65	Recent TakoTsubo syndrome and lipoprotein apheresis: An alert for a safe procedure. European Journal of Preventive Cardiology, 2020, 27, 444-446.	0.8	2
66	HeFH in real life, how to: More evolocumab than authorized. European Journal of Preventive Cardiology, 2020, 27, 2079-2080.	0.8	2
67	Daptomycin-based aminoglycoside-sparing therapy for streptococcal endocarditis: a retrospective multicenter study. Journal of Chemotherapy, 2021, 33, 435-439.	0.7	2
68	Acute effect of lipoprotein apheresis on coronary flow velocity reserve evaluated by the cold pressure test. European Journal of Preventive Cardiology, 2020, 28, 204748732093162.	0.8	2
69	Blood ozonization in patients with mild to moderate COVID-19 pneumonia: a single centre experience: reply. Internal and Emergency Medicine, 2021, 16, 795-796.	1.0	2
70	Lipoprotein(a) in familial hypercholesterolemia: Tips from family history. Revista Portuguesa De Cardiologia, 2021, 40, 225-227.	0.2	2
71	Valor diagnóstico de la reserva de flujo coronario mediante eco-dipiridamol en la hipercolesterolemia homocigota familiar. Revista Espanola De Cardiologia, 2021, 74, 347-349.	0.6	2
72	Is treating severe He FH so easy? A combined treatment between lipoprotein apheresis and PCSK9 inhibitors. Transfusion and Apheresis Science, 2021, , 103258.	0.5	2

#	Article	IF	Citations
73	Acute coronary syndrome and lipid-lowering therapy in a realistic diagnostic-therapeutic care pathway. Pharmacological Research, 2021, 171, 105763.	3.1	2
74	Factor VII Deficiency, Masked by Warfarin Therapy, as a Cause of Bleeding After Cardiovascular Intervention. CardioVascular and Interventional Radiology, 2013, 36, 1180-1183.	0.9	1
75	Cognitive impairment and polidistrectual atherosclerotic disease in chylomicronemia syndrome: A case report. Transfusion and Apheresis Science, 2013, 49, 323-327.	0.5	1
76	A "giant―cause of acute myocardial infarction. Acta Cardiologica, 2017, 72, 355-356.	0.3	1
77	Accuracy of point-of-care ultrasound to identify the source of infection in septic patients: a prospective study—comment. Internal and Emergency Medicine, 2017, 12, 1335-1336.	1.0	1
78	Direct oral anticoagulants in lipoprotein apheresis: handle with care. Internal and Emergency Medicine, 2019, 14, 1171-1173.	1.0	1
79	A neglected outbreak in a long-term care facility: Scabies. American Journal of Infection Control, 2019, 47, 853-854.	1.1	1
80	Inherited atherogenic dyslipidemias: are they correctly reported?. European Journal of Preventive Cardiology, 2020, , 2047487320930308.	0.8	1
81	<scp>COVID</scp> â€19 swab collection and serological screening in lipoprotein apheresis unit. Journal of Clinical Apheresis, 2020, 35, 382-383.	0.7	1
82	Peripherally inserted central catheter (PICC) and midline: Experience in a cardiopulmonary critical care unit. Journal of Vascular Access, 2021, , 112972982199397.	0.5	1
83	Familial LCAT deficiency and cardiovascular disease: the game is not over. A case of dramatic multivessel atherosclerosis. Minerva Medica, 2020, , .	0.3	1
84	Coronary microcirculatory blood flow significantly increases upon acute and chronic cholesterol lowering. evaluation by cadmium-zinc-telluride cardiac imaging stress test. European Journal of Preventive Cardiology, 2022, , .	0.8	1
85	Calcifi ed apical cardiomyopathy. Acta Cardiologica, 2015, 70, 359-359.	0.3	0
86	Multiple silent atherosclerotic aneurysms with penetrating ulcer of the aortic arch treated with a hybrid procedure. Cor Et Vasa, 2016, 58, e505-e508.	0.1	0
87	Appropriateness of empirical therapy in carbapenem-resistant Klebsiella pneumoniae intensive care unit acquired infection: role of surveillance cultures. Infectious Diseases, 2016, 48, 643-645.	1.4	0
88	A case of â€~anaphylacticâ€like' reaction during LDL apheresis: a pathophysiological hypothesis on white wine containing metabisulphite. Transfusion Medicine, 2016, 26, 460-461.	0.5	0
89	Noninvasive Ventilation in Cardiac Procedures: Key Technical and Practical Implications. , 2016, , 599-605.		0
90	Medication-induced hypertriglyceridemia in special circumstances of emergency cardiovascular care. Minerva Anestesiologica, 2017, 83, 890.	0.6	0

#	Article	IF	CITATIONS
91	Peritoneal dialysis as successful treatment in patient with end-stage congestive heart failure due to endomyocardial fibrosis. Cor Et Vasa, 2019, 61, 93-94.	0.1	O
92	Reader response: Low-density lipoprotein cholesterol and risk of intracerebral hemorrhage: A prospective study. Neurology, 2020, 95, 96.2-97.	1.5	0
93	The management of heterozygous familial hypercholesterolaemia with high lipoprotein (a) and statin intolerance. The guidelines a mirage?. European Journal of Preventive Cardiology, 2021, 28, e16-e18.	0.8	O
94	Vascular access in lipoprotein apheresis: Save the vein save the life. Journal of Vascular Access, 2021, 22, 324-325.	0.5	0
95	Comment on "Homozygous familial hypercholesterolemia with severe involvement of the aortic valve: A siblingâ€controlled case study on the efficacy of lipoprotein apheresisâ€. Journal of Clinical Apheresis, 2021, 36, 219-220.	0.7	0
96	Lipoprotein(a) in familial hypercholesterolemia: Tips from family history. Revista Portuguesa De Cardiologia (English Edition), 2021, 40, 225-227.	0.2	0
97	Diagnostic value of coronary flow reserve determined by echo dipyridamole stress in homozygous familial hypercholesterolemia. Revista Espanola De Cardiologia (English Ed), 2021, 74, 347-349.	0.4	0
98	Patients with diabetes mellitus and atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants. Acta Cardiologica, 2021, , 1-1.	0.3	0
99	Takotsubo Syndrome in Patient with Severe Mitral and Aortic Regurgitation. Journal of Cardiovascular Echography, 2018, 28, 72.	0.1	0
100	High-risk NSTEMI due to subclavian artery atherothrombosis in a prior coronary artery bypass graft patient. Journal of Cardiovascular Echography, 2019, 29, 86.	0.1	0
101	Achilles tendon xeroradiography in familial hypercholesterolemia: old tool for new questions. Gazzetta Medica Italiana Archivio Per Le Scienze Mediche, 2020, 179, .	0.0	0
102	Doctors and their children: the Pandora's jar of infectious diseases. Minerva Pediatrics, 2021, , .	0.2	0
103	Lipoprotein(a) apheresis restores coronary microcirculation in refractory angina. Revista Portuguesa De Cardiologia, 2022, 41, 437-439.	0.2	0
104	Paradoxical effect of lipid lowering therapy in homozygous familial hypercholesterolemia: Atherosclerotic plaque calcifications and increased cardiovascular events. Revista Portuguesa De Cardiologia, 2022, 41, 805-807.	0.2	0